Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA Filing

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest analysis on the stock here.

Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome

Kyverna Therapeutics, Inc. shares surged on strong Phase 2 KYSA-8 data for Miv-cel in stiff person syndrome. Read why KYTX stock is a Buy.
IEEE

Safety-Prioritized Optimization of Asteroid Sample Site Selection Using Genetic Algorithm and Variable Neighborhood Tabu Search

Abstract: Sample site selection is crucial for asteroid sample return missions, requiring a strategy that considers factors such as terrain and illumination for mission safety. However, the lack of ...
Journal of Medical Internet Research

Sample Size Requirements for Popular Classification Algorithms in Tabular Clinical Data: Empirical Study

Objective: This study aimed to determine optimal sample sizes and the relationships between sample size and dataset-level characteristics over a variety of binary classification algorithms. Methods: A ...
IEEE

Data Disclosure Under Perfect Sample Privacy

Abstract: Perfect data privacy seems to be in fundamental opposition to the economical and scientific opportunities related to extensive data exchange. This paper defies this intuition by developing ...
The New York Times

The Data on Self-Driving Cars Is Clear. We Have to Change Course.

Dr. Slotkin is a neurosurgeon. I recently got called to see a teenager ejected in a rollover car crash. The trauma team rushed him into surgery to stop major abdominal bleeding, but we all knew. When ...